Nerelimomab
Based on 1 publication(s) in Google Scholar
Nerelimomab (BAYX1351) is an anti-TNF-α antibody. Nerelimomab can be used for research of sepsis.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 162774-06-3
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Nerelimomab
MoreVer todos los productos específicos de isoformas TNF Receptor
More
Actividad biológica
Human IgG1 kappa
Human
TNF
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Baboon model of recurrent bacteremia (Challenged with E.coli)[1]
-
Dosage:7.5 mg/kg
-
Administration:i.v. infusion
-
Result:Improved organ function and attenuated cytokine and plasminogen activator inhibitor release.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-nd
ELISA, FACS, Functional assay
Chemical Information
-
No. CAS 162774-06-3
-
SMILES
[Nerelimomab]
-
Synonyms
BAYX1351
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Pharmaceuticals (Basel)
Nerelimomab Alleviates Capsaicin-Induced Acute Lung Injury by Inhibiting TNF Signaling and Apoptosis. [Abstract]2024 Dec 15;17(12):1694. PMID: 39770536
Pureza y Documentación
Referencias
[1]. Schlag G, et al. Anti-tumor necrosis factor antibody treatment of recurrent bacteremia in a baboon model. Shock. 1994 Jul;2(1):10-8; discussion 19-22. [Content Brief]
[2]. Cohen J, et al. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med. 1996 Sep;24(9):1431-40. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)